Vascular in Biological Technology

Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia

... directed by Prof. K. S. Vijayaragavan, Chief of vascular Surgery at Sri Ramachandra University and met all ... percentage of these patients with peripheral vascular disease are between the ages of 40 to 50. They ... be presented in October at the Indian Society of vascular Surgery where the therapy will be considered for ...

Cappella Inc. Secures $17.3 Million Series C Investment

... Sidebranch stent for the treatment of Bifurcated vascular Disease in Europe and to advance key R&D ... solutions for the treatment of bifurcation vascular disease - an area of high unmet medical need." ... Artery Disease (CAD) and specifically bifurcation vascular disease. The Company's initial product is the ...

ThromboGenics NV: Business Update

... of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business ... with advanced cancer. Microplasmin for vascular Disease - Initial partnering discussions. ... for the treatment of eye disease, vascular disease and cancer. The Company's lead product ...

CryoLife Reports Record First Quarter Revenues of $26.7 Million

... quarter of 2008. The increase in cardiac and vascular tissue processing revenues was primarily due to increased revenues from vascular tissue in the first quarter of 2009 of $7.9 ... look for opportunities to expand our cardiac and vascular surgery portfolios." 2009 Financial ...

Cytopia Presentation on VDA CYT997 at AACR Conference

... that it will present data on its anticancer vascular disrupting agent (VDA) CYT997 at the forthcoming ... effects and mode of action of a Phase II vascular disrupting agent outlines extensive preclinical ... The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of ...

New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando

... Presentation Number: 1036-264 Abstract Title: vascular Dysfunction Measured by Digital Thermal ... Presentation Number: 1040-102 Abstract Title: vascular Dysfunction Measured by Digital Thermal ... of Oxidized LDL Biomarkers, Persistent vascular Dysfunction Measured by Fingertip Digital Thermal ...

Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer

... randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) NPI-2358 in combination ... The ADVANCE (Assessment of Docetaxel and vascular Disruption in Non-Small Cell Lung Cancer) trial ... additional Phase 2 studies this year. About vascular Disrupting Agents (VDA) ...

Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting

... Powerful Multi-Wavelength Workstation Combines vascular Treatment, Hair Removal and Skin Rejuvenation in ... of the industry's most powerful workstations for vascular treatment, hair removal and skin rejuvenation. ... for hair removal, pigmented lesion removal and vascular lesion removal is expected to increase from $650 ...

CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008

... December 31, 2007. Combined cardiac and vascular tissue processing revenues for the fourth quarter ... on hospital budgets. Combined cardiac and vascular tissue processing revenues for the year ended ... to increased demand for the Company's cardiac and vascular processed tissues, the introduction of the ...

Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results

... of $5.3 million, consisting primarily of sales of vascular closure product components to St. Jude Medical, ... of $9.2 million, consisting primarily of sales of vascular closure product components to St. Jude Medical, ... the inventor and developer of the Angio-Seal(TM) vascular Closure Device, which is licensed to St. Jude ...

CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone

... lifestyle. In addition, cryopreserved allograft vascular tissues have enabled patients with impaired ... living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The ... agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, ...

ev3 Inc. Appoints John L. Miclot to Board of Directors

... partner for identifying and treating peripheral vascular and neurovascular disease." About ev3 ... and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are ... specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The ...

Terumo Interventional Systems Launches a Complete Line of Coronary Diagnostic Catheters

... Cardiology at Miami Baptist Cardiac & vascular Institute. With a simple clockwise or ... Cardiologists and vascular Surgeons are among the medical professionals who ... intervention in previously unreachable vascular beds. Terumo Medical Corporation ...

Resverlogix Board of Directors Update

... drugs in the treatment of atherosclerosis and vascular disorders such as Alzheimer's disease, vascular dementia, stroke, and Peripheral Artery Disease ... augment reverse cholesterol transport (RCT) from vascular beds. About Resverlogix Corp. ...

RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

... drugs in the treatment of atherosclerosis and vascular disorders such as Alzheimer's disease, vascular ... augment reverse cholesterol transport (RCT) from vascular beds. About Alzheimer's Disease Every 71 ... Peripheral Artery Disease and other vascular disorders. The Company's secondary focus is ...

Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today

... - Current Treatment Fails to Abolish Majority of vascular Risk - Residual Risk Reduction Initiative (R3i) ... for Action to Reduce the Lipid-Related Residual vascular Risk Unaddressed by Current Standards of Care in ... little, if any, additional impact on residual vascular risk. Therefore, we urgently need new strategies ...

The Medicare Hospital-Acquired Conditions Initiative Will Spur Increased Patient Screening and Potentially Increased Antibiotic Use

... Most Concerned About Lack of Reimbursement for vascular Catheter-Associated Infections, According to a ... acquired during a hospital stay, including vascular catheter-associated ... to no longer reimburse the cost of treating vascular catheter-associated infections. "Physicians we ...

Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval

... Institute announced today that its Division of vascular Surgery was the first to implant, in Phoenix, the ... M.D., Vascular Surgeon and Director of Peripheral vascular Services at Arizona Heart Institute and Arizona ... to prevent rupture and are typically treated by a vascular surgeon with either open surgical repair or less ...

ev3 Inc. Reports Third Quarter 2008 Financial Results

... net product sales increased by 26% and peripheral vascular net sales, excluding atherectomy increased by ... artery lesions. Sales Review Peripheral vascular segment product sales in the third quarter of ... atherectomy revenue of $21.0 million, peripheral vascular product sales increased 19% to $45.9 million in ...

CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007

... processing revenues. Combined cardiac and vascular tissue processing revenues in the third quarter ... the third quarter of 2007. Combined cardiac and vascular tissue processing revenues in the first nine ... agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, ...

Cardica Announces Fiscal 2009 First Quarter Financial Results

... and we are looking toward the launch of the Cook vascular Access Closure Device (CVCD) in Europe," ... devices with Cook Medical to facilitate vascular closure and other surgical procedures. ... surgery, the planned launch of the Cook vascular Access Closure Device (CVCD) in Europe and the ...

CPC of America Announces Agreement with BC Tech for Manufacture of MedClose(TM) Vascular Closure System

... BC Tech will manufacture the MedClose(TM) vascular closure system (VCS), a Class II extravascular ... of the MedClose(TM) system to meet other vascular closure needs and, thereby, our opportunities for ... development of its MedClose(TM) vascular closure system, (2) the Company's expectations ...

HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City

... physicians include local radiologists and vascular specialists trained at identifying ... safe, and currently the best tool available for vascular and bone density screening in a mobile ... and continuing to create awareness about vascular disease through free educational workshops. Above ...

Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award

... Innovation Award is presented to Israel-based vascular Biogenics Ltd. for developing the vascular Targeting System (VTS(TM)). This unique platform ... as well as diseases of the arteries." vascular Biogenics has been able to build a broad pipeline ...

Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing

... to treat severe sun damage, sagging skin, vascular dyschromia and wrinkles MOUNTAIN VIEW, Calif., ... textural irregularities, pigmented lesions and vascular dyschromia. The industry's first minimally ... of photodamage - wrinkles, lines, pigment, and vascular irregularities, all in a single treatment." The ...

CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007

... to increased demand for the Company's cardiac and vascular processed tissues, the introduction of the ... processing revenues. Combined cardiac and vascular tissue processing revenues in the second quarter ... the second quarter of 2007. Combined cardiac and vascular tissue processing revenues in the first six ...

Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates

... and marketer of medical devices for cardiac and vascular surgery. The company is headquartered in Ann ... of Japan focused exclusively on the cardiac and vascular markets, including Terumo Heart Inc., developer ... and Vascutek, Ltd, leading manufacturer of vascular grafts. For more information, visit ...

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent

... Capek. "With one of the largest, most seasoned vascular sales forces in the United States and with the ... world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by ...

Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing

... Commercialization of Expanded Portfolio of vascular Products ... developing and marketing innovative specialty vascular devices, today announced its name change and the ... as the company completed the acquisition of two vascular product development companies and the closing of ...

EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board

... Professor of Surgery, and Director of the vascular Surgery Training Program at the University of ... Board of Surgery with Special Qualifications in vascular Surgery. His areas of active research interest ... noninvasive evaluation of peripheral vascular disease, hemodialysis access, treatment of ...

Cardium Launches New AWARE Clinical Study Website

... Ridgewood); New York (Lenox Hill Heart & vascular Institute, New York; University of Rochester ... Inc., Oklahoma City); Oregon (Providence Heart & vascular Institute, Portland); Pennsylvania (Geisinger ... Care, Burlington); Washington (Swedish Heart and vascular Clinic, Seattle); and Wisconsin (Care Foundation, ...

Peripheral Vascular Device Market Insights Webinar

... June 2 /PRNewswire/ -- WHAT: PERIPHERAL vascular DEVICE MARKET INSIGHTS WEBINAR ... Webinar outlining our knowledge of the peripheral vascular (PV) device industry. Sign up to gain information derived from our Global Peripheral vascular Device report series and PV Marketrack(TM). In ...

Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System

... today announced the launch of the StarClose(R) SE vascular Closure System, a next-generation vessel closure ... StarClose SE to advance the secure closure of the vascular access site following catheterization ... world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment ...

ThromboGenics N.V. - Business Update

... company focused on innovative treatments for vascular disease, eye disease and cancer, is today issuing ... of our clinical pipeline of innovative vascular biopharmaceuticals. These milestones will ... into an important player in the areas of vascular disease, eye disease and cancer." ThromboGenics ...

University Hospitals Case Medical Center, Cleveland, USA and Cardialysis BV, Rotterdam, the Netherlands Enter Strategic Alliance to Found Cardialysis Cleveland

... the United States. University Hospitals Heart & vascular Institute is dedicated to breakthrough ... environments including angiography, IVUS (intra vascular ultrasound) and IVUS related techniques (such as ... and registries in the coronary and peripheral vascular devices as well as in drug trials. The combined ...

NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments

... on a shared commitment to excellence in vascular interventions, the partnership addresses the ... care delivery informatics instruments allow vascular specialists to reach out to consumers and ... new advances in early detection and treatments in vascular disease. The partnership will allow for ...

ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance

... in the pre-FoxHollow acquisition peripheral vascular business segment and the neurovascular ... of SilverHawk, the ability of our U.S. peripheral vascular sales organization to take advantage of cross- ... of therapy solutions to treat peripheral vascular and neurovascular disease. We also will focus ...

LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase

... Inc. (Nasdaq: LMAT ), a provider of peripheral vascular devices and implants, today announced financial ... and dialysis access category and 31% in its vascular category, while general surgery revenues ... from newly acquired products and core open vascular surgery devices drove revenue in the quarter, as ...

Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance

... recently acquired CardioVations product line. vascular sales grew 8.9 percent to $22.0 million compared ... heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 ... 16.8 4.6 27.4% - 21.4 vascular 22.0 20.2 1.8 8.9% ...

Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology

... effects on reducing retinal inflammation and vascular leakage. Charlesson is developing a sustained ... "Our core philosophy is that inflammation and vascular leakage in the retina are early pathogenic ... disease. Inhibition of retinal inflammation and vascular leakage has thus become a new target ...